Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- BWX Technologies Inc's (NYSE:BWXT) subsidiary BWXT Medical Ltd. has agreed with Bayer AG (OTC:BAYRY) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products. The financial terms of the agreement were not disclosed.
- The companies to broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other products.
- Ac-225 is a radioisotope used in targeted alpha therapies (TATs), an emerging class of radionuclide therapy for various tumors with a high unmet medical need.
- Bayer's oncology franchise includes six marketed products, including Xofigo and several other TATs in different stages of development.
- The parties plan to finalize the terms of the commercial agreements at a later date.
- Price Action: BWXT shares traded higher by 1.97% at $55.79 on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!